PSNL - Exact Natera Personalis and Veracyte higher as Truist launch buy coverage

Exact Sciences (EXAS), Natera (NTRA), Personalis (PSNL), and Veracyte (VCYT) are all trading sharply higher today, as Truist Securities initiates coverage with buy recommendations on the stocks.With a price target of $65 and ~21.4% of upside to the previous close, the only laggard in the list, NeoGenomics (NEO) is trading flat today. The firm expects NeoGenomics to benefit ‘from the large, growing oncology lab testing market’ in 2021.For Veracyte, giving a $61 price target, Truist projects a total addressable market of $36B for the company given its ‘strong product pipeline with the Nasal Swab Classifier.’Natera should benefit as reimbursement guidelines start to include average and low-risk pregnancies, the analysts write giving a price target of ~$143 per share, ~42.7% of upside to the previous close.‘With the ability to sequence a factor of 40x more genes than its closest competitors,’ Personalis has no reimbursement risk, the analysts argue, giving a price

For further details see:

Exact, Natera, Personalis and Veracyte higher as Truist launch buy coverage